PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva

ISSN
0171-5216
Date Issued
2020-03
Author(s)
Czogalla, Bastian
Pham, Deborah
Trillsch, Fabian
Rottmann, Miriam
Burges, Alexander
Mahner, Sven
Kirchner, Thomas
Jeschke, Udo
Mayr, Doris
Schmoeckel, Elisa
DOI
10.1007/s00432-020-03126-9
Abstract
Programmed death-ligand 1 (PD-L1) has become a widely used predictive biomarker for therapy with checkpoint inhibitors in a variety of cancers. Here, we studied the expression of PD-L1 in squamous cell carcinomas of the vulva (SCCV) with regard to HPV status via its surrogate marker p16. Additionally, the status of PD-L1 and p16 were analyzed for prognostic information and potential correlation to tumor-infiltrating lymphocytes (TILs).